ANI Pharmaceuticals Files 8-K on Financials
Ticker: ANIP · Form: 8-K · Filed: Nov 20, 2024 · CIK: 1023024
| Field | Detail |
|---|---|
| Company | Ani Pharmaceuticals Inc (ANIP) |
| Form Type | 8-K |
| Filed Date | Nov 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, operations
TL;DR
ANI Pharma dropped an 8-K detailing financial condition and operations. Check it out.
AI Summary
ANI Pharmaceuticals, Inc. filed an 8-K on November 20, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company, formerly known as BioSante Pharmaceuticals Inc. and Ben Abraham Technologies Inc., is incorporated in Delaware and headquartered in Baudette, Minnesota.
Why It Matters
This filing provides crucial updates on ANI Pharmaceuticals' financial performance and operational status, which can influence investor decisions and market perception.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any unusual or immediate risks.
Key Numbers
- 58-2301143 — I.R.S. Employer Identification No. (Company identification number)
- 001-31812 — SEC File Number (Company's SEC filing identifier)
Key Players & Entities
- ANI Pharmaceuticals, Inc. (company) — Registrant
- November 20, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Baudette, Minnesota (location) — Principal Executive Offices
- BioSante Pharmaceuticals Inc. (company) — Former Company Name
- Ben Abraham Technologies Inc. (company) — Former Company Name
FAQ
What specific financial results or conditions are being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.
What is the primary purpose of this 8-K filing?
The primary purpose is to report on the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements/exhibits.
When was ANI Pharmaceuticals, Inc. incorporated?
ANI Pharmaceuticals, Inc. was incorporated in Delaware.
What were ANI Pharmaceuticals, Inc.'s former names?
The company was formerly known as BioSante Pharmaceuticals Inc. and Ben Abraham Technologies Inc.
Where are ANI Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at 210 Main Street West, Baudette, Minnesota, 56623.
Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-11-20 07:00:30
Filing Documents
- ani-20241120.htm (8-K) — 29KB
- exhibit991investordeck11.htm (EX-99.1) — 47KB
- exhibit991investordeck11001.jpg (GRAPHIC) — 61KB
- exhibit991investordeck11002.jpg (GRAPHIC) — 225KB
- exhibit991investordeck11003.jpg (GRAPHIC) — 236KB
- exhibit991investordeck11004.jpg (GRAPHIC) — 138KB
- exhibit991investordeck11005.jpg (GRAPHIC) — 99KB
- exhibit991investordeck11006.jpg (GRAPHIC) — 123KB
- exhibit991investordeck11007.jpg (GRAPHIC) — 93KB
- exhibit991investordeck11008.jpg (GRAPHIC) — 67KB
- exhibit991investordeck11009.jpg (GRAPHIC) — 100KB
- exhibit991investordeck11010.jpg (GRAPHIC) — 106KB
- exhibit991investordeck11011.jpg (GRAPHIC) — 112KB
- exhibit991investordeck11012.jpg (GRAPHIC) — 147KB
- exhibit991investordeck11013.jpg (GRAPHIC) — 124KB
- exhibit991investordeck11014.jpg (GRAPHIC) — 125KB
- exhibit991investordeck11015.jpg (GRAPHIC) — 89KB
- exhibit991investordeck11016.jpg (GRAPHIC) — 130KB
- exhibit991investordeck11017.jpg (GRAPHIC) — 140KB
- exhibit991investordeck11018.jpg (GRAPHIC) — 124KB
- exhibit991investordeck11019.jpg (GRAPHIC) — 135KB
- exhibit991investordeck11020.jpg (GRAPHIC) — 146KB
- exhibit991investordeck11021.jpg (GRAPHIC) — 172KB
- exhibit991investordeck11022.jpg (GRAPHIC) — 171KB
- exhibit991investordeck11023.jpg (GRAPHIC) — 56KB
- exhibit991investordeck11024.jpg (GRAPHIC) — 163KB
- exhibit991investordeck11025.jpg (GRAPHIC) — 143KB
- exhibit991investordeck11026.jpg (GRAPHIC) — 87KB
- exhibit991investordeck11027.jpg (GRAPHIC) — 56KB
- 0001023024-24-000106.txt ( ) — 4853KB
- ani-20241120.xsd (EX-101.SCH) — 2KB
- ani-20241120_lab.xml (EX-101.LAB) — 21KB
- ani-20241120_pre.xml (EX-101.PRE) — 12KB
- ani-20241120_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On November 20, 2024, Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, Inc., will present at the 2024 Jefferies London Healthcare Conference in London, UK. A copy of the investor presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*
01
Item 7.01 Regulation FD Disclosure The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*
01 Exhibits
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Investor Presentation, dated N ovember 20 , 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 20, 2024 ANI PHARMACEUTICALS, INC. By: /s/ Stephen P. Carey Name: Stephen P. Carey Title: Senior Vice President Finance and Chief Financial Officer